Economic burden of contrast-induced nephropathy: Implications for prevention strategies

Journal of Medical Economics

Volumn 10, Issue 2, 2007, Pages 119-134

  Subramanian, Sujha ^a   Tumlin, James ^b,c   Bapat, Bela ^a   Zyczynski, Teresa ^d  

^a RTI INTERNATIONAL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c Southeast Renal Research Institute SERRI   (United States)

^d GE HEALTHCARE   (United States)

Author keywords

Contrast induced nephropathy; Economic burden; Outcomes

Indexed keywords

ARTICLE; CARCINOMA IN SITU; CONTRAST ENHANCEMENT; DECISION MAKING; ECONOMIC ASPECT; HEALTH CARE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; KIDNEY DISEASE; MORBIDITY; MORTALITY;

EID: 34447551578     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/200710119134     Document Type: Article

References (31)

1. Rich MW, Crecelius CA. Incidence, risk factors and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older: a prospective study. Archives of Internal Medicine 1990; 150: 1237-1242.
2. Tumlin J, Stacul F, Adam A et al. Pathophysiology of contrast-induced nephropathy. American Journal of Cardiology 2006; 98(6A): 14K-20K.
3. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality: a cohort analysis. Journal of the American Medical Association 1996; 275: 1489-1494.
4. McCullough PA, Wolyn R, Rocher LL et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. American Journal of Medicine 1997; 103: 368-375.
5. Powe NR, Moore RD, Steinberg EP. Adverse reactions to contrast media: factors that determine the cost of treatment. American Journal of Roentgenology 1993; 161: 1089-1095.
6. Powe NR, AJ Davidoff, RD Moore et al. Net costs from three perspectives of using low versus high osmolality contrast medium in diagnostic angiocardiography. Journal of the American College of Cardiology 1993; 21: 101-109.
7. Caro JJ, Trindade E, McGregor M. The cost-effectiveness of replacing high-osmolality with low-osmolality contrast media. American Journal of Roentgenology 1992; 159: 869-874.
8. Barrett BJ, Parfrey PS, Foley RN et al. An economic analysis of strategies for the use of contrast media for diagnostic cardiac catheterization. Medical Decision Making 1994; 14: 325-335.
9. Steinberg EP, Moore RD, Powe NR et al. Safety and cost effectiveness of high-osmolality as compared with low-osmolality contrast material in patients undergoing cardiac angiography. New England Journal of Medicine 1992; 326: 425-430.
10. Aspelin P, Aubry P, Fransson SG et al. Cost-effectiveness of iodixanol in patients at high risk of contrast-induced nephropathy. American Heart Journal 2000; 149: 298-303.
11. Mehran R, Aymong ED, Nikolsky E et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. Journal of the American College of Cardiology 2004; 44: 1393-1399.
12. Josephson SA, Dillon WP, Smith WS. Incidence of contrast nephropathy from cerebral CT angiography and CT perfusion imaging. Neurology 2005; 64: 1805-1806.
13. Bartholomew BA, Harjai KJ, Dukkipati S et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. American Journal of Cardiology 2004; 93: 1515-1519.
14. Mueller C, Buerkle G, Perruchoud AP et al. Female sex and risk of contrast nephropathy after percutaneous coronary intervention. Canadian Journal of Cardiology 2004; 20: 505-509.
15. Rihal CS, Textor SC, Grill DE et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 165: 2259-2264.
16. Dangas G, Iakovou I, Nikolsky E et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. American Journal of Cardiology 2005; 95: 13-19.
17. Lindsay J, Apple S, Pinnow EE et al. Percutaneous coronary intervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatinine. Catheterization and Cardiovascular Interventions 2003; 59: 338-343.
18. Iakovou I, Dangas G, Mehran R et al. Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. Journal of Invasive Cardiology 2003; 15: 18-22.
19. Aspelin P, Aubry P, Fransson SG et al; Nephrotoxicity in High-Risk Patients Study of Iso-Osmolar and Low-Osmolar Non-Ionic Contrast Media Study Investigators. Nephrotoxic effects in high-risk patients undergoing angiography. New England Journal of Medicine 2003; 348: 491-499.
20. Rudnick MR, JS Berns, RM Cohn et al. Contrast media-associated nephrotoxicity. Seminars in Nephrology 1997; 17: 15-26.
21. Parfrey PS, Griffiths SM, Barrett BJ et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. New England Journal of Medicine 1989; 320: 143-149.
22. Gruberg L, Mintz GS, Mehran R et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. Journal of the American College of Cardiology 2000; 36: 1542-1548.
23. Gruberg L, Mehran R, Dangas G et al. Acute renal failure requiring dialysis after percutaneous coronary interventions. Catheterization and Cardiovascular Interventions 2001; 52: 409-416.
24. Nikolsky E, Mehran R. Understanding the consequences of contrast induced nephropathy. Reviews in Cardiovascular Medicine 2003; 4(Suppl. 5): S10-S18.
25. Iakovou I, Dangas G et al. Incidence, predictors, and economic impact of contrast induced nephropathy: results in 8,628 patients treated with percutaneous coronary interventions. Journal of the American College of Cardiology 2002; 39(Suppl. 1): 2-2(1).
26. Kugelmass AD, Cohen DJ, Brown PP et al. Hospital resources consumed in treating complications associated with percutaneous coronary interventions. American Journal of Cardiology 2006; 97: 322-327.
27. Subramanian S, Khandker R, Roth D. Long-term resource use and cost of percutaneous transluminal coronary angioplasty versus stenting in the elderly: a retrospective claims data analysis. Value in Health 2003; 6: 534-541.
28. Shih YT, Guo A, Just PM et al. Impact of initial dialysis modality and modality switches on Medicare expenditures of end stage renal disease patients. Kidney International 2005; 68: 319-329.
29. Candrilli S, Mauskopf J. How much does a hospital day cost? 11th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR); 2006; Philadelphia, PA, USA.
30. Zirogiannis PN, Rentoukas EI, Lazaros GA. Contrast media induced nephropathy in patients undergoing cardiac catheterisation. Hellenic Journal of Cardiology 2004; 45: 107-113.
31. Soloman R, Barrett B. Follow-up of patients with contrast-induced nephropathy. Kidney International. Supplement 2006; 100: S46-S50.